Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC - Get Free Report)'s share price traded down 7.8% during mid-day trading on Monday . The company traded as low as $3.62 and last traded at $3.74. 130,935 shares changed hands during mid-day trading, an increase of 30% from the average session volume of 100,957 shares. The stock had previously closed at $4.05.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on shares of Cyclacel Pharmaceuticals in a report on Saturday, May 10th. They set a "sell" rating for the company.
Read Our Latest Stock Report on Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Stock Performance
The company's 50-day moving average is $4.18 and its 200 day moving average is $5.46. The company has a market capitalization of $464.43 million, a PE ratio of -0.24 and a beta of 0.52.
Cyclacel Pharmaceuticals (NASDAQ:CYCC - Get Free Report) last announced its quarterly earnings data on Wednesday, April 2nd. The biotechnology company reported ($5.28) EPS for the quarter, missing the consensus estimate of ($4.64) by ($0.64). The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.
Cyclacel Pharmaceuticals Dividend Announcement
The business also recently announced a dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 29th were issued a $2.40 dividend. The ex-dividend date was Tuesday, April 29th. Cyclacel Pharmaceuticals's dividend payout ratio is currently -4.29%.
Insider Buying and Selling
In related news, CEO David E. Lazar sold 12,164,301 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.48, for a total value of $5,838,864.48. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 68.00% of the stock is currently owned by corporate insiders.
About Cyclacel Pharmaceuticals
(
Get Free Report)
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Recommended Stories
Before you consider Cyclacel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cyclacel Pharmaceuticals wasn't on the list.
While Cyclacel Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
